Baseline Interleukin‐10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease‐Modifying Antirheumatic Drug Naive and Anti–Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis
Authors' conclusion
Treatment with abatacept and MTX resulted in significantly greater reduction of biomarkers relevant to RA, and high baseline IL-10 levels predicted better treatment response with abatacept and MTX versus placebo and MTX across clinical outcomes.
Study context
- Population
- DMARD-naive, ACPA-positive patients with early rheumatoid arthritis (RA)
- Participants
- 446 vs 300
- Comparison
- Abatacept + methotrexate (MTX) vs placebo + MTX
- Abatacept and MTXn = 446
- Placebo and MTXn = 300reference
- Primary endpoint
- Biomarkers associated with baseline disease activity and baseline biomarkers predictive of treatment response
- Follow-up
- Week 52
Methodological detailsexploratory post hoc analysis, phase 3
- Exploratory post hoc analysis
- Phase 3
Primary result
As reported in the abstract
- Biomarkers with significant reduction in pharmacodynamic (PD) changes with abatacept + MTX vs placebo + MTX (of 103)
- 47
- Of these, biomarkers correlated with baseline disease activity
- 18
- High baseline IL-10 associated with greater probability of achieving efficacy measures by week 52 with abatacept + MTX vs placebo + MTX
- P < 0.03 to P < 0.0007
Original publication
Baseline Interleukin‐10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease‐Modifying Antirheumatic Drug Naive and Anti–Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis. Arthritis Rheumatol. Published 17 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →